OliX Grants Hansoh Pharma Exclusive Rights to Two siRNA Sequences, With Room for More

OliX Pharmaceuticals has signed an agreement granting China’s Hansoh Pharma the rights to develop and commercialize two short interfering RNA (siRNA) sequences, a deal struck separately from the co-development arrangement the two companies already have in place. The structure is notable for what it leaves open: the contract allows for additional technology transfers directed at the same biological targets, meaning the initial handover of two sequences could grow into a broader pipeline relationship rather than a one-off license.

One Exclusive Sequence Per Program, Not a Platform Handover

Under the new agreement, Hansoh receives exclusive rights to one siRNA sequence for each of the two newly contracted programs. That framing matters for how the deal should be read. Rather than licensing out an entire discovery platform, OliX is transferring specific, defined molecules while retaining the underlying chemistry and design capabilities that produced them. The arrangement gives Hansoh a clear, protectable asset for each program, while OliX keeps the option of generating further candidates against the same targets.

siRNA drugs work by silencing disease-causing genes at the messenger RNA level, a modality that has moved from scientific curiosity to a commercially validated class over the past decade. For a Korean biotech of OliX’s size, out-licensing defined sequences to a larger partner with regional development and manufacturing muscle is a capital-efficient way to advance programs without shouldering full clinical costs.

The Follow-On Clause Is the Strategic Center of the Deal

Both companies emphasized that follow-on development and additional business arrangements against the same targets remain possible. In practice, this converts a two-sequence license into an open channel: if either program advances, or if a first-generation sequence needs a successor with improved potency or durability, Hansoh has a contractual path to take additional OliX molecules rather than starting a new negotiation from scratch.

For OliX, that clause functions as a built-in expansion mechanism. Each additional transfer would presumably carry its own commercial terms, so the deal’s ultimate value depends less on the initial signing than on how the two programs perform. It also deepens a relationship that predates this contract, since the companies were already co-developing assets together before carving out these two new programs under a separate agreement.

Terms Still Undisclosed, Execution Still Ahead

Financial terms were not disclosed in the initial reports, and neither the targets nor the intended indications of the two sequences have been publicly specified. Those omissions leave the most important valuation questions unanswered: whether the deal carries meaningful upfront payments, how development milestones are staged, and what royalty economics OliX would retain on any commercialized product.

What can be said now is directional. OliX is converting its siRNA discovery output into partnered programs with a repeat counterparty, and it has structured the relationship so that success in the first two programs creates a ready-made route to further transfers. The next signposts will be disclosure of the deal’s economics and any indication of which disease areas the two sequences address.